Drug Search Results
More Filters [+]

EMA401

Alternative Names: ema401
Latest Update: 2024-03-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: AT2 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Spinifex Pty
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for EMA401

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Neuralgia|Peripheral Nervous System Diseases|Neuralgia, Postherpetic|Chemotherapy-induced Peripheral Neuropathy|Neuropathic Pain|Pain Unspecified

Phase 1: Neuralgia, Postherpetic|Neuropathic Pain

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

JapicCTI-173816

P2

Terminated

Neuralgia

2020-08-28

EMPHENE

P2

Completed

Neuralgia

2019-07-16

EMPADINE

P2

Terminated

Peripheral Nervous System Diseases

2019-03-25

EMPADINE

P2

Completed

Pain Unspecified

2019-03-25

Recent News Events